Annovis Bio (ANVS) Competitors $2.35 +0.03 (+1.29%) As of 01:45 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ANVS vs. ALXO, MDWD, EPRX, CCCC, DERM, AARD, BDTX, IPHA, SCLX, and NLTXShould you be buying Annovis Bio stock or one of its competitors? The main competitors of Annovis Bio include ALX Oncology (ALXO), MediWound (MDWD), Eupraxia Pharmaceuticals (EPRX), C4 Therapeutics (CCCC), Journey Medical (DERM), Aardvark Therapeutics (AARD), Black Diamond Therapeutics (BDTX), Innate Pharma (IPHA), Scilex (SCLX), and Neoleukin Therapeutics (NLTX). These companies are all part of the "pharmaceutical products" industry. Annovis Bio vs. Its Competitors ALX Oncology MediWound Eupraxia Pharmaceuticals C4 Therapeutics Journey Medical Aardvark Therapeutics Black Diamond Therapeutics Innate Pharma Scilex Neoleukin Therapeutics ALX Oncology (NASDAQ:ALXO) and Annovis Bio (NYSE:ANVS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation. Which has more risk and volatility, ALXO or ANVS? ALX Oncology has a beta of 1.11, suggesting that its share price is 11% more volatile than the S&P 500. Comparatively, Annovis Bio has a beta of 1.65, suggesting that its share price is 65% more volatile than the S&P 500. Which has better valuation and earnings, ALXO or ANVS? Annovis Bio is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioALX OncologyN/AN/A-$134.85M-$2.20-0.49Annovis BioN/AN/A-$24.59M-$2.04-1.15 Does the media prefer ALXO or ANVS? In the previous week, ALX Oncology had 1 more articles in the media than Annovis Bio. MarketBeat recorded 3 mentions for ALX Oncology and 2 mentions for Annovis Bio. ALX Oncology's average media sentiment score of 0.34 beat Annovis Bio's score of 0.00 indicating that ALX Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ALX Oncology 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Annovis Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is ALXO or ANVS more profitable? ALX Oncology's return on equity of -115.67% beat Annovis Bio's return on equity.Company Net Margins Return on Equity Return on Assets ALX OncologyN/A -115.67% -84.82% Annovis Bio N/A -206.01%-158.26% Do insiders & institutionals believe in ALXO or ANVS? 98.0% of ALX Oncology shares are held by institutional investors. Comparatively, 15.8% of Annovis Bio shares are held by institutional investors. 21.0% of ALX Oncology shares are held by insiders. Comparatively, 20.8% of Annovis Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Do analysts rate ALXO or ANVS? ALX Oncology currently has a consensus price target of $3.30, indicating a potential upside of 206.98%. Annovis Bio has a consensus price target of $17.33, indicating a potential upside of 637.59%. Given Annovis Bio's higher possible upside, analysts clearly believe Annovis Bio is more favorable than ALX Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ALX Oncology 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83Annovis Bio 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60 SummaryALX Oncology beats Annovis Bio on 9 of the 13 factors compared between the two stocks. Get Annovis Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for ANVS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ANVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANVS vs. The Competition Export to ExcelMetricAnnovis BioMED IndustryMedical SectorNYSE ExchangeMarket Cap$45.80M$3.13B$5.76B$21.62BDividend YieldN/A2.37%5.86%3.50%P/E Ratio-1.1521.2776.8730.16Price / SalesN/A254.45451.6254.27Price / CashN/A45.4837.2224.68Price / Book3.519.6813.774.59Net Income-$24.59M-$53.02M$3.29B$999.97M7 Day Performance-1.47%0.78%0.48%0.70%1 Month Performance-12.80%5.27%4.84%5.31%1 Year Performance-71.89%12.01%83.79%15.71% Annovis Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANVSAnnovis Bio2.1749 of 5 stars$2.35+1.3%$17.33+637.6%-73.3%$45.80MN/A-1.153ALXOALX Oncology3.5445 of 5 stars$1.05-0.9%$3.30+214.3%-51.8%$56.76MN/A-0.4840MDWDMediWound1.5683 of 5 stars$17.14-3.9%$32.25+88.2%-9.8%$192.81M$20.22M-6.4980Positive NewsEPRXEupraxia Pharmaceuticals2.2735 of 5 stars$5.30-0.4%$11.00+107.5%+99.3%$191.13MN/A-6.2429CCCCC4 Therapeutics3.1952 of 5 stars$3.57+34.2%$8.67+142.8%-47.7%$189.31M$35.58M-2.26150News CoveragePositive NewsAnalyst UpgradeGap UpHigh Trading VolumeDERMJourney Medical2.2012 of 5 stars$7.12+0.1%$12.17+70.9%+39.6%$187.06M$56.40M-18.7490AARDAardvark Therapeutics3.7396 of 5 stars$9.95+15.8%$32.60+227.6%N/A$186.38MN/A0.0018Positive NewsHigh Trading VolumeBDTXBlack Diamond Therapeutics3.5294 of 5 stars$3.19-1.8%$11.67+265.7%-34.5%$185.04MN/A13.8790Gap UpIPHAInnate Pharma2.4637 of 5 stars$2.07+3.3%$11.00+432.7%-7.2%$184.37M$21.77M0.00220News CoveragePositive NewsAnalyst ForecastSCLXScilex2.4052 of 5 stars$25.70-2.2%$455.00+1,670.4%-31.4%$182.80M$56.59M-0.8980Positive NewsNLTXNeoleukin TherapeuticsN/A$19.00-5.4%N/A-56.7%$178.56MN/A-6.1190High Trading Volume Related Companies and Tools Related Companies ALX Oncology Competitors MediWound Competitors Eupraxia Pharmaceuticals Competitors C4 Therapeutics Competitors Journey Medical Competitors Aardvark Therapeutics Competitors Black Diamond Therapeutics Competitors Innate Pharma Competitors Scilex Competitors Neoleukin Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:ANVS) was last updated on 9/18/2025 by MarketBeat.com Staff From Our PartnersWhy Peter Thiel Hid Gold in a VaultSilicon Valley billionaires hiding gold in vaults? Peter Thiel’s Palantir quietly diverted tens of millions...Golden Portfolio | SponsoredREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredWhat a Former CIA Agent Knows About the Coming Collapse This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThis Crypto Could Thrive as Global Tensions Rise Right as capital begins to rotate back into crypto, my top...Crypto 101 Media | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Annovis Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Annovis Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ANVS Stock Alerts